Neurolutions

Neurolutions is a neurotechnology company based in St. Louis, Missouri, focused on developing brain-computer interface solutions for neurological rehabilitation. The company's flagship product, the IpsiHand Upper Extremity Rehabilitation System, is a non-invasive BCI-powered exoskeleton designed to help stroke survivors recover hand and arm motor function. The system works by detecting brain signals associated with the patient's intent to move, then translating those signals into assisted movement through the exoskeleton, effectively leveraging neuroplasticity to promote functional recovery. This approach targets one of the most persistent and debilitating consequences of stroke, offering a technology-driven alternative to conventional physical therapy.

Neurolutions has secured notable regulatory and commercial validation for its technology, most prominently through the FDA's Breakthrough Device designation for the IpsiHand system. This designation reflects the device's potential to address an unmet clinical need and has helped accelerate its path toward broader adoption in clinical stroke rehabilitation settings. The company has raised $20 million in Series B funding, signaling meaningful investor confidence in both the technology and the market opportunity. IpsiHand is actively used in clinical environments, positioning Neurolutions among a small group of BCI companies that have successfully bridged the gap between research-stage development and real-world patient care.

Neurolutions represents an important proof point for the broader neurotechnology industry, demonstrating that non-invasive BCI systems can achieve regulatory recognition and clinical deployment within one of medicine's most challenging therapeutic areas. Stroke affects millions of people globally each year, and the limited options for restoring motor function after the acute recovery window make solutions like IpsiHand highly significant. By combining BCI technology with rehabilitation medicine, Neurolutions is helping to define a new category of neurological care that extends beyond symptom management toward meaningful functional restoration. Their progress offers a credible template for how neurotech companies can navigate clinical validation, regulatory pathways, and commercial adoption in tandem.